Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2B investigator lead study using psychedelics psilocybin and lysergic acid diethylamide ("LSD") to treat Parkinson's Disease

X
Trial Profile

A Phase 2B investigator lead study using psychedelics psilocybin and lysergic acid diethylamide ("LSD") to treat Parkinson's Disease

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lysergide (Primary) ; Psilocybin (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Dec 2020 New trial record
    • 02 Dec 2020 According to a Silo Pharma media release, Dr. Kim Kuypers will serve as Investigator Sponsor for the Phase 2B study. The company expects to share additional information regarding protocol, ethics submission and initiation of the study as the information becomes available.
    • 02 Dec 2020 According to a Silo Pharma media release, the company has entered into an investigator-sponsored study agreement with Maastricht University of the Netherlands. The research project is a clinical study to examine the effects of repeated low doses of psilocybin and LSD on cognitive and emotional dysfunctions in Parkinson's disease and to understand its mechanism of action.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top